Advertisement

Racial Diversity in Hepatocellular Carcinoma in a Predominately African-American Population at an Urban Medical Center

  • Brian RutledgeEmail author
  • Jenny Jan
  • Sindhuri Benjaram
  • Neha Sahni
  • Paul Naylor
  • Philip Philip
  • Murray Ehrinpreis
  • Milton Mutchnick
Original Research
  • 15 Downloads

Abstract

Purpose

Surveillance, treatment, and outcomes for African-American (AA) populations with hepatocellular carcinoma (HCC) remain under evaluated. This study evaluated demographics, surveillance, therapy, and outcomes for a predominately AA population.

Methods

The electronic medical records of a large health-care provider were used to identify 274 patients with visits for HCC between 2010 and 2017. Tumor size at diagnosis was defined by imaging with ≤ 5 cm being defined as “small.” Surveillance for HCC was defined based on ultrasound (US) assessments.

Results

Patients were primarily AA (78%) and male (76%) with an average age at diagnosis of 62 years. Hepatitis C virus (HCV) was more likely to be a risk factor for the development of HCC in AA as compared to non-AA (92% vs 67%; p < 0.005). Surveillance rates were low (16% for AA vs 7% for non-AA). An aspartate aminotransferase platelet ratio index (APRI) value > 0.7 within 2 years of tumor diagnosis was a strong predictor for the risk of the development of HCC (86% AA vs 79 % non-AA). In this study, race was not a factor in treatment or outcomes, and most patients received tumor ablative treatment.

Conclusion

Given the low surveillance rates and the demonstrated increased survival for patients with small tumors, ways to increase surveillance must be initiated. The results of this study demonstrate the need for physician/patient education on the importance of surveillance US. Further, this study supports routine assessment of APRI in AA patients in an effort to identify patients in whom intensive surveillance will significantly improve earlier detection of tumors.

Keywords

African-American Hepatocellular carcinoma Ultrasound (US) 

Notes

Acknowledgment

This abstract was presented at the Digestive Disease Week in Chicago, IL, USA, on May 8, 2017, and was published as Abstract Mo1419.

Author Contributions

Drs. Brian Rutledge, Neha Sahni, Paul Naylor, Philip Philip, Murray Ehrinpreis, and Milton Mutchnick were responsible for the conception and design of the study and interpretation of data analysis and drafting of the manuscript. Dr. Paul Naylor was responsible for the data analysis. Drs. Jenny Jan and Sindhuri Benjaram made substantial contributions to the acquisition of the data and also subsequent analysis and interpretation of the data along with being responsible for the revisions and critical review of the drafts. All authors have approved the final version of this manuscript.

Funding Information

This research was supported in part by an individual investigator-initiated grant from Gilead Sciences to Dr. Milton Mutchnick and Dr. Paul Naylor. Dr. Milton Mutchnick is a member of the Speaker’s Bureau for Abbvie, CLDF, Gilead, and Intercept.

Compliance with Ethical Standards

Statement of Ethics

This original research article is in compliance with the guidelines for human studies and in accordance with the World Medical Association Declaration of Helsinki. The subjects of this study have not been referred to by their real name, and further no identifying image has been included in this report.

Conflict of Interest

The authors declare that they have no conflict(s) of interest.

References

  1. 1.
    Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.  https://doi.org/10.3322/caac.21492.CrossRefPubMedGoogle Scholar
  2. 2.
    Njei B, Rotman Y, Ditah I, Lim JK. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology. 2015;61(1):191–9.  https://doi.org/10.1002/hep.27388.CrossRefPubMedGoogle Scholar
  3. 3.
    Alazawi W, Cunningham M, Dearden J, Foster GR. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther. 2010;32(3):344–55.  https://doi.org/10.1111/j.1365-2036.2010.04370.x.CrossRefPubMedGoogle Scholar
  4. 4.
    Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013;47(Suppl):S2–6.  https://doi.org/10.1097/MCG.0b013e3182872f29.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. J Carcinog. 2017;16:1.  https://doi.org/10.4103/jcar.JCar_9_16.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature. 2005;436(7053):946–52.  https://doi.org/10.1038/nature04079.CrossRefPubMedGoogle Scholar
  7. 7.
    Sloane D, Chen H, Howell C. Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival. J Natl Med Assoc. 2006;98(12):1934–9.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Xu L, Kim Y, Spolverato G, Gani F, Pawlik TM. Racial disparities in treatment and survival of patients with hepatocellular carcinoma in the United States. Hepatobiliary Surg Nutr. 2016;5(1):43–52.  https://doi.org/10.3978/j.issn.2304-3881.2015.08.05.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Mathur AK, Osborne NH, Lynch RJ, Ghaferi AA, Dimick JB, Sonnenday CJ. Racial/ethnic disparities in access to care and survival for patients with early-stage hepatocellular carcinoma. Arch Surg. 2010;145(12):1158–63.  https://doi.org/10.1001/archsurg.2010.272.CrossRefPubMedGoogle Scholar
  10. 10.
    Ha J, Yan M, Aguilar M, Bhuket T, Tana MM, Liu B, et al. Race/ethnicity-specific disparities in cancer incidence, burden of disease, and overall survival among patients with hepatocellular carcinoma in the United States. Cancer. 2016;122(16):2512–23.  https://doi.org/10.1002/cncr.30103.CrossRefPubMedGoogle Scholar
  11. 11.
    Howlader NNA, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD, . https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission, posted to the SEER web site, April 2019.
  12. 12.
    Estevez J, Yang JD, Leong J, Nguyen P, Giama NH, Zhang N, et al. Clinical features associated with survival outcome in African-American patients with hepatocellular carcinoma. Am J Gastroenterol. 2019;114(1):80–8.  https://doi.org/10.1038/s41395-018-0261-y.CrossRefPubMedGoogle Scholar
  13. 13.
    Winters AC, Sung JC, Wyatt B, Berera D, Schiano TD, Schwartz ME, et al. At diagnosis of hepatocellular carcinoma, African Americans with hepatitis C have better liver function than other patients. Clin Liver Dis (Hoboken). 2018;12(4):109–12.  https://doi.org/10.1002/cld.745.CrossRefGoogle Scholar
  14. 14.
    Rich NE, Hester C, Odewole M, Murphy CC, Parikh ND, Marrero JA, et al. Racial and ethnic differences in presentation and outcomes of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2019;17(3):551–559.e551.  https://doi.org/10.1016/j.cgh.2018.05.039.CrossRefPubMedGoogle Scholar
  15. 15.
    Reddy N, Naylor P, Hakim Z, Asbahi R, Ravindran K, May E, et al. Effect of treatment for CHC on liver disease progression and hepatocellular carcinoma development in African Americans. J Clin Transl Hepatol. 2015;3(3):163–8.  https://doi.org/10.14218/jcth.2015.00013.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Stubbs A, Naylor P, Ravindran K, Benjaram S, Reddy N, Mutchnick S, et al. Racial diversity in mortality and morbidity in urban patients with hepatitis C. J Viral Hepat. 2016;23(6):439–46.  https://doi.org/10.1111/jvh.12504.CrossRefPubMedGoogle Scholar
  17. 17.
    Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.  https://doi.org/10.1002/hep.24199.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med. 1996;101(4):422–34.  https://doi.org/10.1016/s0002-9343(96)00197-0.CrossRefPubMedGoogle Scholar
  19. 19.
    Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, Fontaine H, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology. 2011;54(6):1987–97.  https://doi.org/10.1002/hep.24545.CrossRefPubMedGoogle Scholar
  20. 20.
    Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, Del Poggio P, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol. 2010;53(2):291–7.  https://doi.org/10.1016/j.jhep.2010.03.010.CrossRefPubMedGoogle Scholar
  21. 21.
    Khalaf N, Ying J, Mittal S, Temple S, Kanwal F, Davila J, et al. Natural history of untreated hepatocellular carcinoma in a US cohort and the role of cancer surveillance. Clin Gastroenterol Hepatol. 2017;15(2):273–281.e271.  https://doi.org/10.1016/j.cgh.2016.07.033.CrossRefPubMedGoogle Scholar
  22. 22.
    Kanwal F, Singal AG. Surveillance for hepatocellular carcinoma: current best practice and future direction. Gastroenterology. 2019.  https://doi.org/10.1053/j.gastro.2019.02.049.CrossRefGoogle Scholar
  23. 23.
    Davila JA, Henderson L, Kramer JR, Kanwal F, Richardson PA, Duan Z, et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med. 2011;154(2):85–93.  https://doi.org/10.7326/0003-4819-154-2-201101180-00006.CrossRefPubMedGoogle Scholar
  24. 24.
    Zhao C, Jin M, Le RH, Le MH, Chen VL, Jin M, et al. Poor adherence to hepatocellular carcinoma surveillance: a systematic review and meta-analysis of a complex issue. Liver Int. 2018;38(3):503–14.  https://doi.org/10.1111/liv.13555.CrossRefPubMedGoogle Scholar
  25. 25.
    EASL clinical practice guidelines: management of hepatocellular carcinoma (2018). J Hepatol 69 (1):182-236.  https://doi.org/10.1016/j.jhep.2018.03.019 CrossRefGoogle Scholar
  26. 26.
    Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317–70.  https://doi.org/10.1007/s12072-017-9799-9.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–80.  https://doi.org/10.1002/hep.29086.CrossRefPubMedGoogle Scholar
  28. 28.
    Covey AM. Hepatocellular carcinoma: updates to screening and diagnosis. 2018;16(5S):663.  https://doi.org/10.6004/jnccn.2018.0052.CrossRefGoogle Scholar
  29. 29.
    Fitzmorris P, Shoreibah M, Anand BS, Singal AK. Management of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2015;141(5):861–76.  https://doi.org/10.1007/s00432-014-1806-0.CrossRefPubMedGoogle Scholar
  30. 30.
    Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.  https://doi.org/10.1056/NEJMoa0708857.CrossRefPubMedGoogle Scholar
  31. 31.
    Costentin CE, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, et al. Compliance with hepatocellular carcinoma surveillance guidelines associated with increased lead-time adjusted survival of patients with compensated viral cirrhosis: a multi-center cohort study. Gastroenterology. 2018;155(2):431–442.e410.  https://doi.org/10.1053/j.gastro.2018.04.027.CrossRefPubMedGoogle Scholar
  32. 32.
    Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T, et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol. 2012;107(2):253–61.  https://doi.org/10.1038/ajg.2011.327.CrossRefPubMedGoogle Scholar
  33. 33.
    Hann HW, Wan S, Lai Y, Hann RS, Myers RE, Patel F, et al. Aspartate aminotransferase to platelet ratio index as a prospective predictor of hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2015;30(1):131–8.  https://doi.org/10.1111/jgh.12664.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of GastroenterologyWayne State University School of MedicineDetroitUSA
  2. 2.Department of OncologyKarmanos Cancer Institute/Wayne State University School of MedicineDetroitUSA

Personalised recommendations